Exiqon Launches New Products for the Research and Development of LNA™ Based Drugs
Complete the form below to unlock access to ALL audio articles.
Exiqon A/S has announced the expansion of its product offering to include LNA™ products for the research and development of RNA targeted medicine including LNA™ as the active pharmaceutical ingredient.
The first new products being offered include the following:
• oxy-LNA™ amidites in kilogram quantities
• LNA™ oligonucleotides in gram quantities
• miRCURY LNA™ microRNA Inhibitors in gram quantities
Exiqon can now also offer fully paid up, non-exclusive, manufacturing licenses to customers who want to manufacture or have manufactured oxy-LNA™ amidites for their research programs.
Exiqon does not grant licenses to the manufacturing, research, development or sale of LNA™ based drugs for clinical trials or otherwise.
In a comment, Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller said: “We are excited to expand our product offering following clarification that Santaris Pharma a/s does not have exclusive rights to supply products for the research and development of LNA™ based drugs. Next generation sequencing technology has revealed the complexity of the transcriptome, however, the biological functionality of the RNA molecules are by far not understood. With these products, Exiqon can now supply customers wishing to conduct high throughput target identification and target validation studies and eventually validate such targets in vivo.”
